Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sogyeonghwalhyeol-tang (SGHH) is a traditional East Asian polyherbal formula composed of 17 medicinal herbs, widely used in Korean and Chinese medicine for its analgesic and anti-inflammatory properties. It is primarily indicated for musculoskeletal conditions such as chronic low back pain, neuralgia, and arthritis. The formula is traditionally believed to improve blood circulation and expel 'wind-dampness' and 'blood stasis.' Modern pharmacological research suggests that SGHH exerts its therapeutic effects by inhibiting pro-inflammatory cytokines and mediators, including COX-2, TNF-alpha, and IL-6. Recent clinical and observational studies have also explored its potential in reducing cardiovascular disease risk in patients with systemic lupus erythematosus (SLE).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sogyeonghwalhyeol-tang.